Kiora Pharmaceuticals Achieves Preclinical Seizure Suppression with KIO-300 in Temporal Lobe Epilepsy Model

Preclinical data from Kiora Pharmaceuticals (NASDAQ: KPRX) indicate that KIO-300, the active pharmaceutical ingredient underpinning its Phase 2 ophthalmology program KIO-301, significantly suppressed epileptiform activity in an ex vivo temporal lobe epilepsy model, a finding that opens a formulation and indication-expansion question for development teams already tracking the asset.

The data, presented as a poster at the Epilepsy Foundation Pipeline Conference on June 18, 2026, in Leesburg, VA, showed statistically significant inhibition of spontaneous epileptiform event frequency beginning 42 minutes post-treatment (p < 0.0001) in hippocampal CA1 slices from mice with induced temporal lobe epilepsy. Cumulative epileptiform burden was also significantly reduced (p < 0.0001), and the suppressive effect persisted through washout periods, suggesting prolonged neural tissue retention.

Critically, KIO-300 did not impair broader electrical transmission in brain tissue, indicating selectivity for pathological spontaneous activity rather than generalized neurological suppression. That selectivity profile will be a central data point for any future IND-enabling toxicology package if Kiora advances toward a CNS development pathway. The scientific rationale draws directly from retinal work: KIO-300 previously reduced pathological retinal hyperactivity by approximately 50%, and neuronal hyperexcitability is a shared mechanistic feature of both retinal degeneration and epilepsy.

For manufacturing and formulation strategists, the more immediate implication is that a single API is now being evaluated across two distinct tissue compartments, ocular and CNS, each carrying different delivery, permeability, and ICH Q8 formulation development requirements. Kiora has stated it retains full development and commercialization rights outside the eye, meaning any CNS program would require an independent regulatory and manufacturing build-out rather than leveraging existing ophthalmic supply chain infrastructure.

The company has indicated that future translational R&D will evaluate targeted molecular modifications and alternative delivery strategies to optimize CNS-specific benefit, which signals that the current KIO-300 molecule may undergo structural or formulation changes before any CNS IND submission.

The pace of those translational steps, and whether preclinical CNS data can be generated at a scale sufficient to support a formal development decision, will determine how quickly this indication-expansion thesis moves from conference poster to regulatory filing.

Source: Kiora Pharmaceuticals, Inc. via IR News Release, June 18, 2026. Data presented at the Epilepsy Foundation Pipeline Conference, June 18–19, 2026, Leesburg, VA.